1. Allotey, J, Stallings, E, Bonet, M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ 2020; 370: m3320.
Google Scholar | Crossref | Medline2. Money, D. Canadian surveillance of COVID-19 in pregnancy: Epidemiology, maternal and infant outcomes. Report #2. Public Health Agency of Canada, 15 January 2021, http://med-fom-ridprogram.sites.olt.ubc.ca/files/2021/01/CANCOVID_Preg-report-2-ON-AB-BC-QC-data_15JAN2021_FINAL.pdf (accessed 24 May 2021).
Google Scholar3. Knight, M, Ramakrishnan, R, Bunch, K, et al. Females in hospital with SARS-CoV-2 infection, the association with pregnancy and pregnancy outcomes: A UKOSS/ISARIC/CO-CIN investigation, 25 March 2020, https://www.gov.uk/government/publications/ukossisaricco-cin-females-in-hospital-with-sars-cov-2-infection-the-association-with-pregnancy-and-pregnancy-outcomes-25-march-2021 (accessed 25 May 2021).
Google Scholar4. Gurol-Urganci, I, Jardine, JE, Carroll, F, et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: National cohort study. Am J Obstet Gynecol 2021;20;225(5):522.e1-522.e11. doi: 10.1016/j.ajog.2021.05.016. Online ahead of print.
Google Scholar | Crossref5. Villar, J, Ariff, S, Gunier, RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr 2021 Aug 1;175(8):817-826. doi: 10.1001/jamapediatrics.2021.1050.
Google Scholar | Crossref6. Jorgensen, SCJ, Kebriaei, R, Dresser, LD. Remdesivir: Review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 2020; 40: 659–671.
Google Scholar | Crossref | Medline7. Beigel, JH, Tomashek, KM, Dodd, LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med 2020; 383: 1813–1826.
Google Scholar | Crossref | Medline8. Goldman, JD, Lye, DCB, Hui, DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med 2020; 383: 1827–1837.
Google Scholar | Crossref | Medline9. Spinner, CD, Gottlieb, RL, Criner, GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020; 324: 1048–1057.
Google Scholar | Crossref | Medline10. Wang, Y, Zhang, D, Du, G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–1578.
Google Scholar | Crossref | Medline11. Consortium, WHOST, Pan, H, Peto, R, et al. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. N Engl J Med 2021; 384: 497–511.
Google Scholar | Crossref | Medline12. Anderson, J, Schauer, J, Bryant, S, et al. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case Rep Womens Health 2020; 27: e00221.
Google Scholar | Medline13. Burwick, RM, Yawetz, S, Stephenson, KE, et al. Compassionate use of remdesivir in pregnant women with severe Covid-19. Clin Infect Dis 2020 Oct 8;ciaa1466. doi: 10.1093/cid/ciaa1466. Online ahead of print.
Google Scholar | Crossref14. Dande, R, Qureshi, A, Persaud, K, et al. Remdesivir in a pregnant patient with COVID-19 pneumonia. J Commun Hosp Intern Med Perspect 2021; 11: 103–106.
Google Scholar | Crossref | Medline15. Igbinosa, I, Miller, S, Bianco, K, et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. Am J Obstet Gynecol 2020; 223: 768–770.
Google Scholar | Crossref | Medline16. Jacobson, J, Antony, K, Beninati, M, et al. Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. Case Rep Womens Health 2021 Jan;29:e00273. doi: 10.1016/j.crwh.2020.e00273. Epub 2020 Nov 25.
Google Scholar | Crossref17. Maldarelli, GA, Savage, M, Mazur, S, et al. Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: Case report and management discussion. Open Forum Infect Dis 2020; 7: ofaa345.
Google Scholar | Crossref | Medline18. McCoy, JA, Short, WR, Srinivas, SK, et al. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States Academic Center. Am J Obstet Gynecol MFM 2020; 2: 100164.
Google Scholar | Crossref | Medline19. Naqvi, M, Zakowski, P, Glucksman, L, et al. Tocilizumab and remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19). Obstet Gynecol 2020; 136: 1025–1029.
Google Scholar | Crossref | Medline20. Pelayo, J, Pugliese, G, Salacup, G, et al. Severe COVID-19 in third trimester pregnancy: Multidisciplinary approach. Case Rep Crit Care 2020; 2020: 8889487.
Google Scholar | Medline21. Pierce-Williams, RAM, Burd, J, Felder, L, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: A United States cohort study. Am J Obstet Gynecol MFM 2020; 2: 100134.
Google Scholar | Crossref | Medline22. Center for Drug Evaluation and Research . Clinical review. NDA 214787. Remdesivir (Veklury). 22 October 2020, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000MedRpdf (accessed 3 May 2021)
Google Scholar23. Center for Drug Evaluation and Research , Department of Health and Human Services Food and Drug Administration. Veklury™ (Remdesivir [RDV]/ GS-5734). Non-clinical pharmacology/toxicology NDA review and evaluation. 8 July 2020, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000PharmRpdf (accessed 30 April 2021).
Google Scholar24. International Maternal Pediatric Adolescent AIDS Clinical Trials Network. IMPAACT 2032. Pharmacokinetics and safety of Remdesivir for treatment of COVID-19 in pregnant and non-pregnant women in the United States. Protocol version 2.0, 18 December 2020, https://www.impaactnetwork.org/sites/default/files/2021-04/IMPAACT_2032_PROTOCOL_FINAL_V2.0_18DEC2020_CM_1.pdf (accessed 1 May 2021).
Google Scholar25. Dornemann, J, Burzio, C, Ronsse, A, et al. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis 2017; 215: 171–174.
Google Scholar | Medline26. Frauenfelder, C, Brierley, J, Whittaker, E, et al. Infant with SARS-CoV-2 infection causing severe lung disease treated with remdesivir. Pediatrics 2020 Sep;146(3):e20201701. doi: 10.1542/peds.2020-1701.
Google Scholar | Crossref27. Group, RC, Horby, P, Lim, WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704.
Google Scholar | Crossref | Medline28. World Health Organization . Corticosteroids for COVID-19. living guidance, 2 September 2020, https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed 22 May 2021).
Google Scholar29. Group WHOREAfC-TW , Sterne, JAC, Murthy, S, Diaz, JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324:1330–1341.
Google Scholar | Crossref | Medline30. Angus, DC, Derde, L, Al-Beidh, F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020; 324: 1317–1329.
Google Scholar | Crossref | Medline31. Ryu, RJ, Easterling, TR, Caritis, SN, et al. Prednisone pharmacokinetics during pregnancy and lactation. J Clin Pharmacol 2018; 58: 1223–1232.
Google Scholar | Crossref | Medline32. Kemp, MW, Newnham, JP, Challis, JG, et al. The clinical use of corticosteroids in pregnancy. Hum Reprod Update 2016; 22: 240–259.
Google Scholar | Medline33. Beitins, IZ, Bayard, F, Ances, IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81: 936–945.
Google Scholar | Crossref | Medline | ISI34. Flint, J, Panchal, S, Hurrell, A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 2016; 55: 1693–1697.
Google Scholar | Crossref | Medline35. Committee on obstetric P. Committee opinion No. 713: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017;130:e102–e1e9.
Google Scholar | Crossref | Medline36. Bandoli, G, Palmsten, K, Forbess Smith, CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am 2017; 43: 489–502.
Google Scholar | Crossref | Medline37. Rodriguez-Pinilla, E, Martinez-Frias, ML. Corticosteroids during pregnancy and oral clefts: A case-control study. Teratology 1998; 58: 2–5.
Google Scholar | Crossref | Medline38. Park-Wyllie, L, Mazzotta, P, Pastuszak, A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385–392.
Google Scholar | Crossref | Medline39. Mossey, PA, Little, J, Munger, RG, et al. Cleft lip and palate. Lancet 2009; 374: 1773–1785.
Google Scholar | Crossref | Medline | ISI40. Hviid, A, Molgaard-Nielsen, D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183: 796–804.
Google Scholar | Crossref | Medline | ISI41. Skuladottir, H, Wilcox, AJ, Ma, C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol 2014; 100: 499–506.
Google Scholar | Crossref | Medline42. Drugs and lactation database (LactMed) [Internet]. Bethesda, MD: National Library of Medicine (US),  https://www.ncbi.nlm.nih.gov/books/NBK501922/ (accessed 22 May 2021).
Google Scholar43. Mitra, AR, Gellatly, R, Rowe, H, et al. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). Obstet Gynecol 2021; 137: 379–380.
Google Scholar | Crossref | Medline44. Center for Drug Evaluation and Research, Department of Health and Human Services Food and Drug Administration. Actemra™ (tocilizumab). Pharmacology NDA review and evaluation. 9 March 2010, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000PharmRpdf (accessed 5 May 2020).
Google Scholar45. Group, RC . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–1645.
Google Scholar | Crossref | Medline46. Investigators, R-C, Gordon, AC, Mouncey, PR, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021; 384: 1491–1502.
Google Scholar | Crossref | Medline47. Hermine, O, Mariette, X, Tharaux, PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med 2021; 181: 32–40.
Google Scholar | Crossref | Medline48. Salvarani, C, Dolci, G, Massari, M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med 2021; 181: 24–31.
Google Scholar | Crossref | Medline49. Salama, C, Han, J, Yau, L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384: 20–30.
Google Scholar | Crossref | Medline50. Stone, JH, Frigault, MJ, Serling-Boyd, NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020; 383: 2333–2344.
Google Scholar | Crossref | Medline51. Veiga, VC, Prats, J, Farias, DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial. BMJ 2021; 372:n84.
Google Scholar | Medline